Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor Ameliorate Metabolic Disorder and Obesity Induced Cardiomyocyte Injury and Mitochondrial Remodeling. This evidence concerns the gene SLC5A2 and obesity due to melanocortin 4 receptor deficiency.